ATE323501T1 - Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen - Google Patents

Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen

Info

Publication number: ATE323501T1
Authority: AT; Austria
Prior art keywords: inflammatory diseases; treatment; pharmaceutical composition; composition containing; inflammatory
Prior art date: 2001-01-30

Application number

AT02705707T

Other languages

English (en)

Inventor

Theoharis C Theoharides

Original Assignee

Theoharis C Theoharides

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-30

Filing date

2002-01-03

Publication date

2006-05-15

2002-01-03 Application filed by Theoharis C Theoharides filed Critical Theoharis C Theoharides

2006-05-15 Application granted granted Critical

2006-05-15 Publication of ATE323501T1 publication Critical patent/ATE323501T1/de

Links

208000027866 inflammatory disease Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title 1
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract 2
210000003630 histaminocyte Anatomy 0.000 abstract 2
FGNPLIQZJCYWLE-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound OS(O)(=O)=O.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FGNPLIQZJCYWLE-BTVCFUMJSA-N 0.000 abstract 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract 1
241000283690 Bos taurus Species 0.000 abstract 1
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract 1
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 abstract 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
229960001570 ademetionine Drugs 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 abstract 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract 1
229960000520 diphenhydramine Drugs 0.000 abstract 1
229930003944 flavone Natural products 0.000 abstract 1
150000002212 flavone derivatives Chemical class 0.000 abstract 1
235000011949 flavones Nutrition 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000004006 olive oil Substances 0.000 abstract 1
235000008390 olive oil Nutrition 0.000 abstract 1
-1 quercetin Chemical class 0.000 abstract 1
229960001285 quercetin Drugs 0.000 abstract 1
235000005875 quercetin Nutrition 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1
VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Botany (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02705707T 2001-01-30 2002-01-03 Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen ATE323501T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/771,669 US6984667B2 (en)	1998-04-08	2001-01-30	Synergistic proteoglycan compositions for inflammatory conditions

Publications (1)

Publication Number	Publication Date
ATE323501T1 true ATE323501T1 (de)	2006-05-15

Family

ID=25092582

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02705707T ATE323501T1 (de)	2001-01-30	2002-01-03	Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen

Country Status (7)

Country	Link
US (7)	US6984667B2 (de)
EP (1)	EP1365777B1 (de)
AT (1)	ATE323501T1 (de)
AU (1)	AU2002239841A1 (de)
DE (1)	DE60210752T2 (de)
ES (1)	ES2261632T3 (de)
WO (1)	WO2002060393A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080153761A1 (en) *	1998-04-08	2008-06-26	Theoharides Theoharis C	Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US20050220908A1 (en) *	2004-03-30	2005-10-06	Theoharides Theoharis C	Anti-inflammatory compositions for multiple sclerosis
US7799766B2 (en) *	1998-04-08	2010-09-21	Theta Biomedical Consulting & Development Co., Inc.	Composition for treating hormonally-dependent cancers
US7906153B2 (en) *	1998-04-08	2011-03-15	Theta Biomedical Consulting & Development Co., Inc.	Anti-inflammatory compositions for treating multiple sclerosis
US6984667B2 (en) *	1998-04-08	2006-01-10	Theta Biomedical Consulting And Development Co.	Synergistic proteoglycan compositions for inflammatory conditions
DE10212502A1 (de) *	2002-03-20	2003-10-02	G O T Therapeutics Gmbh	Verwendung von mindestens einem Flavonoid des Quercetins zur Erhöhung des Spiegels von nützlichen kurzkettigen Fettsäuren (SCFA) im unteren Intestinaltrakt
US20030229030A1 (en) *	2002-06-11	2003-12-11	Theoharides Theoharis C.	Method of treating interleukin-6-mediated inflammatory diseases
US20040253296A1 (en) *	2002-09-11	2004-12-16	Martin Kenneth A.	Food bar for treating musculoskeletal disorders
US7485629B2 (en) *	2002-10-16	2009-02-03	Arthrodynamic Technologies, Animal Health Division, Inc.	Composition and method for treatment of joint damage
US7504387B2 (en) *	2002-10-16	2009-03-17	Arthrodynamic Technologies, Animal Health Division, Inc.	Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
US7326734B2 (en) *	2003-04-01	2008-02-05	The Regents Of The University Of California	Treatment of bladder and urinary tract cancers
US7976880B2 (en) *	2003-06-04	2011-07-12	Ramaswamy Rajendran	Pregnane glycoside compositions and Caralluma extract products and uses thereof
WO2005007676A2 (en) *	2003-07-10	2005-01-27	Rajadhyaksha V J	Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
ES2223291B1 (es) *	2003-08-06	2006-03-16	Bioiberica, S.A.	Nuevo uso terapeutico de condroitin sulfato.
US20050158376A1 (en) *	2003-10-23	2005-07-21	Sardi William F.	Dietary supplement and method of processing same
US20090169585A1 (en) *	2003-10-23	2009-07-02	Resveratrol Partners, Llc	Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
WO2005095959A2 (en) *	2004-03-29	2005-10-13	Howard Murad	Methods for treating dermatological conditions in a patient
US20050220912A1 (en) *	2004-03-30	2005-10-06	Theoharides Theoharis C	Anti-inflammatory composition for treating pelvic endometriosis
US20050220907A1 (en) *	2004-03-30	2005-10-06	Theoharides Theoharis C	Implanted medical devices with anti-inflammatory coatings
JP2005290331A (ja) *	2004-04-06	2005-10-20	Shinto Fine Co Ltd	抗アレルゲン組成物及びアレルゲン不活性化方法
GB0411166D0 (en) *	2004-05-19	2004-06-23	Bionovate Ltd	Treatment for asthma and arthritis
ES2534603T3 (es) *	2004-06-30	2015-04-24	E-L Management Corp.	Composiciones cosméticas y procedimientos que comprenden Rhodiola Rosea
WO2006020588A1 (en) *	2004-08-09	2006-02-23	Creagri, Inc.	Olive compositions and methods for treating inflammatory conditions
KR101154616B1 (ko)	2004-12-31	2012-06-08	(주)아모레퍼시픽	캄페롤 및 퀘르세틴을 함유하는 히알루론산 생성 촉진용조성물
CN101227916A (zh) *	2005-05-24	2008-07-23	维尔金有限公司	预防和治疗发炎相关状况的组合物和方法
US9789149B2 (en) *	2005-07-19	2017-10-17	Creagri, Inc.	Vegetation water composition for treatment of inflammatory skin conditions
US20090069638A1 (en) *	2005-12-02	2009-03-12	Howard Murad	Diagnostic and Treatment Regimen for Achieving Body Water Homeostasis
ITMI20061030A1 (it)	2006-05-26	2007-11-27	Altergon Sa	Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
DE102006060953A1 (de) *	2006-12-12	2008-08-07	Farco-Pharma Gmbh	Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
US20080227747A1 (en) *	2007-03-15	2008-09-18	Tabbiner Philip	Composition and methods for treating or preventing degenerative joint and cardiovascular conditions
WO2008151107A2 (en) *	2007-06-01	2008-12-11	Massachusetts Institute Of Technology	High-resolution flexural stage for in-plane position and out-of-plane pitch/roll alignment
US20090082738A1 (en) *	2007-09-24	2009-03-26	Vad Vijay B	Natural Anti-Inflammatory Agents for Reducing Pain
EP2231136A1 (de) *	2007-12-12	2010-09-29	DSM IP Assets B.V.	Zusammensetzungen mit hydroxytyrosol und chondroitin und ihre verwendung zur behandlung, begleitenden behandlung oder prävention von entzündlichen erkrankungen
AU2009231634B2 (en)	2008-04-04	2014-05-15	University Of Utah Research Foundation	Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
CA2723315A1 (en) *	2008-04-30	2009-11-05	Ben-Gurion University Of The Negev Research And Development Authority	Vascular delivery systems
US10517839B2 (en) *	2008-06-09	2019-12-31	Cornell University	Mast cell inhibition in diseases of the retina and vitreous
US9050275B2 (en) *	2009-08-03	2015-06-09	Theta Biomedical Consulting & Development Co., Inc.	Methods of screening for and treating autism spectrum disorders and compositions for same
WO2011049629A2 (en) *	2009-10-22	2011-04-28	Api Genesis, Llc	Methods of making and using compositions comprising flavonoids
CA2830933A1 (en)	2011-03-23	2012-09-27	University Of Utah Research Foundation	Methods for treating or preventing urological inflammation
US8916528B2 (en)	2011-11-16	2014-12-23	Resveratrol Partners, Llc	Compositions containing resveratrol and nucleotides
US9295684B2 (en) *	2012-06-07	2016-03-29	Ming-Chen Lee	Cream composition enhancing skin absorption of glucosamine
CA2947308A1 (en)	2013-05-09	2014-11-13	Zeenar Enterprises Pty Ltd	Niacin formulation
JPWO2015046486A1 (ja) *	2013-09-30	2017-03-09	サンスター株式会社	肥満抑制組成物
JP2016153384A (ja) *	2015-02-20	2016-08-25	花王株式会社	ウロプラキン発現促進剤
US11337994B2 (en)	2016-09-15	2022-05-24	University Of Utah Research Foundation	In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
US10729693B2 (en) *	2018-03-02	2020-08-04	Ponce Medical School Foundation, Inc.	Compositions and methods for the treatment of endometriosis
CN111228653A (zh)	2018-11-13	2020-06-05	格莱科米拉治疗公司	用电离辐射加强癌症治疗的方法
CN119454686A (zh) *	2024-08-06	2025-02-18	广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院）	山柰酚或含有山柰酚的组合物在制备治疗和/或缓解多发性硬化症药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1273669A (en) *	1916-11-27	1918-07-23	Robert W Prittie	Composition of matter.
US3067106A (en) *	1959-04-07	1962-12-04	Foundation For Prosthetic Res	Skin treating method and composition
CA1036941A (en) *	1974-05-03	1978-08-22	Joseph Nastasi	Anti-inflammatory preparation
US4265823A (en) *	1979-01-04	1981-05-05	Robert E. Kosinski	Aurothiosteroids
GB8332265D0 (en) *	1983-12-02	1984-01-11	Biorex Laboratories Ltd	Pharmaceutical compositions
US5110814A (en) *	1989-01-11	1992-05-05	Asta Pharma Ag	Azelastine and its salts used to combat psoriasis
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
US5250529A (en) *	1990-02-08	1993-10-05	Kos Pharmaceuticals, Inc.	Method alleviating migraine headache with mast cell degranulation blocking agents
DE4106026A1 (de) *	1991-02-26	1992-08-27	Plantamed Arzneimittel Gmbh	Pharmazeutische zubereitungen enthaltend eine gallussaeureverbindung und/oder quercetin sowie verfahren zur isolierung dieser verbindungen
US5994357A (en) *	1991-11-05	1999-11-30	Theoharides; Theoharis C.	Method of treatment for interstitial cystitis
CA2100657A1 (en) *	1991-11-15	1993-05-16	Glen M. Hartung	Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
US5223257A (en) *	1992-03-11	1993-06-29	Vasu Arora	Topical composition for relieving aches and pains
KR19990067704A (ko) *	1992-12-17	1999-08-25	디. 제이. 우드, 스피겔 알렌 제이	부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
TW370529B (en) *	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
US5648355A (en) *	1994-02-09	1997-07-15	Kos Pharmaceutical, Inc.	Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
IT1273742B (it) *	1994-08-01	1997-07-09	Lifegroup Spa	Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose
US6403599B1 (en) *	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
US5795905A (en) *	1995-06-06	1998-08-18	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods relating thereto
US5980865A (en) *	1995-08-18	1999-11-09	Baker Norton Pharmaceuticals, Inc.	Method for treating late phase allergic reactions and inflammatory diseases
US5855884A (en) *	1995-11-27	1999-01-05	Kos Pharmaceuticals, Inc.	Treatment of stress-induced migraine headache with a corticotropin releasing hormone blocker
US6020305A (en) *	1996-08-06	2000-02-01	Kos Pharmaceuticals, Inc.	Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors
US5804594A (en) *	1997-01-22	1998-09-08	Murad; Howard	Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
CA2280093A1 (en) *	1997-02-04	1998-08-06	John V. Kosbab	Compositions and methods for prevention and treatment of vascular degenerative diseases
US5843959A (en) *	1997-03-19	1998-12-01	University Of Florida Research Foundation, Inc.	Methods and bicyclic polyamine compositions for the treatment of inflammation
NZ335823A (en) *	1997-04-22	2001-06-29	Neurocrine Biosciences Inc	Thiophenopyridines, preparation as CRF receptor antagonists
US6984667B2 (en) *	1998-04-08	2006-01-10	Theta Biomedical Consulting And Development Co.	Synergistic proteoglycan compositions for inflammatory conditions
US6689748B1 (en) *	1998-04-08	2004-02-10	Theoharis C. Theoharides	Method of treating mast cell activation-induced diseases with a proteoglycan
US7115278B2 (en) *	1998-04-08	2006-10-03	Theoharis C Theoharides	Proteoglycan compositions for the treatment of cardiovascular inflammatory diseases
US6391864B1 (en) *	1998-08-19	2002-05-21	Joint Juice, Inc.	Food supplement containing a cartilage supplement
DE19839443A1 (de) *	1998-08-29	2000-03-02	Miklos Ghyczy	Arnzneimittel mit entzündungshemmender Wirkung
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6136795A (en) *	1998-11-18	2000-10-24	Omni Nutraceuticals, Inc	Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US6162787A (en) *	1999-04-02	2000-12-19	Immudyne, Inc.	Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
US6492429B1 (en) *	2000-07-10	2002-12-10	N.V. Nutricia	Composition for the treatment of osteoarthritis
US6696074B2 (en) *	2000-12-04	2004-02-24	Tei Biosciences, Inc.	Processing fetal or neo-natal tissue to produce a scaffold for tissue engineering
WO2004071532A1 (en) *	2003-02-13	2004-08-26	Licentia Oy	Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses

2001
- 2001-01-30 US US09/771,669 patent/US6984667B2/en not_active Expired - Lifetime
2002
- 2002-01-03 AT AT02705707T patent/ATE323501T1/de not_active IP Right Cessation
- 2002-01-03 WO PCT/US2002/000476 patent/WO2002060393A2/en not_active Ceased
- 2002-01-03 EP EP02705707A patent/EP1365777B1/de not_active Expired - Lifetime
- 2002-01-03 ES ES02705707T patent/ES2261632T3/es not_active Expired - Lifetime
- 2002-01-03 AU AU2002239841A patent/AU2002239841A1/en not_active Abandoned
- 2002-01-03 DE DE60210752T patent/DE60210752T2/de not_active Expired - Lifetime
- 2002-12-27 US US10/329,367 patent/US6624148B2/en not_active Expired - Lifetime
- 2002-12-27 US US10/329,366 patent/US6645482B2/en not_active Expired - Lifetime
- 2002-12-27 US US10/329,387 patent/US6641806B2/en not_active Expired - Lifetime
- 2002-12-27 US US10/329,386 patent/US6635625B2/en not_active Expired - Lifetime
2003
- 2003-07-02 US US10/610,909 patent/US20040005355A1/en not_active Abandoned
2004
- 2004-03-30 US US10/811,859 patent/US20050042312A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030113392A1 (en)	2003-06-19
US20030104088A1 (en)	2003-06-05
WO2002060393A2 (en)	2002-08-08
US6984667B2 (en)	2006-01-10
AU2002239841A1 (en)	2002-08-12
EP1365777A2 (de)	2003-12-03
EP1365777B1 (de)	2006-04-19
US20030104087A1 (en)	2003-06-05
DE60210752D1 (de)	2006-05-24
US20030099732A1 (en)	2003-05-29
ES2261632T3 (es)	2006-11-16
US6645482B2 (en)	2003-11-11
US20020176902A1 (en)	2002-11-28
US6624148B2 (en)	2003-09-23
US6641806B2 (en)	2003-11-04
DE60210752T2 (de)	2007-04-12
WO2002060393A3 (en)	2003-03-20
US6635625B2 (en)	2003-10-21
US20050042312A1 (en)	2005-02-24
WO2002060393B1 (en)	2003-11-27
US20040005355A1 (en)	2004-01-08

Legal Events

Date	Code	Title	Description
2006-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE323501T1 (de)	2006-05-15	Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen
CR10838A (es)	2009-11-05	Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
BR9803198A (pt)	2000-03-28	Composto, processos para preparar o mesmo e para combater fungo ou uma doença fúngica de plantas em um local, e, composição.
BRPI0509172A (pt)	2007-08-28	pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
ATE380542T1 (de)	2007-12-15	Topische zusammensetzung enthaltend mindestens ein vitamin d oder vitamin d analogon und mindestens ein corticosteroid
DE60313597D1 (de)	2007-06-14	Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
DE60333937D1 (de)	2010-10-07	Substituierte quinazolinone verbindungen
BRPI0518406A2 (pt)	2008-11-18	composiÇÕes tendo uma alta eficÁcia antiviral e antibacteriana
BR0312464A (pt)	2005-05-03	Inibidores de tirosina quinases
ES2570856T3 (es)	2016-05-20	Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
BRPI0415758A (pt)	2006-12-19	combinações de substáncias ativas fungicidas sinergìsticas
SV1999000048A (es)	2000-07-04	Uso de dihidropiriminas como medicamento y nuevas sustancias ref. lea 32 791-sv
BRPI0911681B8 (pt)	2021-05-25	composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro
BRPI0415121A (pt)	2006-11-28	material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
CL2007002617A1 (es)	2008-05-16	Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
ATE249214T1 (de)	2003-09-15	Pentafluorobenzensulfonamide und analoge
CY1114133T1 (el)	2016-07-27	ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
CL2008002984A1 (es)	2009-06-05	Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
ATE272628T1 (de)	2004-08-15	Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
BRPI0408499A (pt)	2006-04-04	solução aquosa estável de um fungicida de polieno
DE60142913D1 (de)	2010-10-07	Arzneilösungen enthaltend modafinilverbindungen
BRPI0414386A (pt)	2006-11-21	composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição
BR0208740A (pt)	2004-07-20	Sistema de camada termoabsorvente
DE602006009259D1 (de)	2009-10-29	Pharmazeutische zusammensetzung mit einem organopoirkstoff
BR0007910A (pt)	2001-11-06	Combinações de substâncias ativas fungicidas